In experimental AD models, exogenous adiponectin or AdipoR agonists yield striking benefits: improved spatial memory, increased hippocampal synaptic density, reduced Aβ deposition and tau phosphorylation, and lower markers of neuroinflammation and oxidative damage [209]. This evidence concerns the gene MAPT and Alzheimer disease.